All Updates

All Updates

icon
Filter
Funding
Matchpoint Therapeutics raised USD 70 million in Series A funding; launches out of stealth
Precision Medicine
Oct 14, 2022
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Oct 14, 2022

Matchpoint Therapeutics raised USD 70 million in Series A funding; launches out of stealth

Funding

  • Drug discovery company Matchpoint Therapeutics launched out of stealth and raised USD 70 million in a Series A funding round led by Sanofi Ventures, with participation from new and existing investors. This funding round brings the total funds raised by the company to USD 100 million. In addition, Jason Hafler, managing director of Sanofi Ventures, will be joining the company’s board of directors. 

  • The new funds will be used to advance the company’s proprietary Advanced Covelent Exploration platform and support the development of the company’s undisclosed drug candidates that are currently in the discovery stage. 

  • Matchpoint is developing small molecule drugs to treat immune diseases using its proprietary Advanced Covalent Exploration platform that integrates chemoproteomics, machine learning algorithms and covalent chemistry. The platform identifies disease-causing proteins for which novel medicines are developed. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.